Afuco™ Anti-RTN4 ADCC Therapeutic Antibody (Ozanezumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized (from mouse) antibody expressed in CHO binding to human Nogo-A. Ozanezumab is a monoclonal antibody designed for the treatment of ALS and multiple sclerosis. Ozanezumab targets a protein called Neurite Outgrowth Inhibitor (NOGO-A) or Reticulon 4. NOGO-A is a protein that in humans is encoded by the RTN4 gene that has been identified as an inhibitor of neurite outgrowth specific to the central nervous system. NOGO-A is found at higher than normal levels in persons with MND.
Supplier | Creative Biolabs |
---|---|
Product # | AFC-TAB-903 |
Pricing | Inquiry |
Host | Human |
Target | RTN4 |
Species Reactivity | Human |
Type | ADCC enhanced antibody |
Applications | IF, IP, Neut, FuncS, ELISA, FC |
Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |